Everyone wants to lose weight, this is what Europe’s most valuable brand is building on
Denmark’s economy has rarely been in a position to depend on the performance of a single company, Novo Nordisk, but the current situation reflects this. The pharmaceutical giant, whose market capitalization is currently 2.88 trillion Danish kroner, exceeds the entire GDP of Denmark, making it the most valuable company in Europe – the Telex article covers this topic.
Economic Effects
In 2023, the company paid more than $2.3 billion in taxes, making a significant contribution to Denmark’s GDP growth. The local statistical office prepares separate analyzes of the industry and its economic effects, which shows the strategic importance of Novo Nordisk.
Media and Social Impact
Novo Nordisk’s products, especially consumer products containing the active ingredient semaglutide, have gained enormous popularity in Hollywood and social media. Related content on TikTok has reached billions, forcing the platform to crack down on influencers promoting such products.
Related news
First eye drop to improve public health gets green light in the United States
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >Wegovy also received approval as a tablet – Novo Nordisk may enter a new era
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >Egis Pharmaceuticals opens new factory in Budapest
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >Related news
Farmers protesting against the EU-Mercosur agreement block several highways in Belgium
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >OKSZ: retail dynamics remain weak, turnaround still awaited
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >KSH: retail turnover in November exceeded the same period of the previous year by 2.5 percent and the previous month by 0.1 percent
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >

